We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
CABAZITAXEL ACCORD, CABAZITAXEL INTAS (Accord Healthcare Pty Ltd)
Product name
CABAZITAXEL ACCORD, CABAZITAXEL INTAS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
138 (255 working days)
Active ingredients
cabazitaxel
Registration type
New generic medicine
Indication
CABAZITAXEL ACCORD, CABAZITAXEL INTAS (injection, concentrated) in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.